- Report
- October 2024
- 183 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- September 2024
- 180 Pages
Global
From €4272EUR$4,500USD£3,603GBP
- Report
- September 2024
- 73 Pages
Asia Pacific
From €2777EUR$2,925USD£2,342GBP
€3085EUR$3,250USD£2,603GBP
- Report
- April 2024
- 505 Pages
Global
€2326EUR$2,450USD£1,962GBP
- Report
- May 2024
- 224 Pages
Global
From €4556EUR$4,799USD£3,843GBP
- Report
- November 2024
- 207 Pages
Global
From €4414EUR$4,650USD£3,724GBP
- Report
- August 2024
- 443 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- December 2024
- 180 Pages
Global
From €4414EUR$4,650USD£3,724GBP
- Report
- October 2024
- 186 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- October 2024
- 186 Pages
Global
From €3365EUR$3,545USD£2,839GBP
€3739EUR$3,939USD£3,154GBP
- Report
- July 2024
- 175 Pages
Global
From €4747EUR$5,000USD£4,004GBP
- Report
- March 2025
- 360 Pages
Global
From €5174EUR$5,450USD£4,364GBP
- Report
- March 2025
- 196 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- August 2024
- 294 Pages
Global
From €3963EUR$4,175USD£3,343GBP
- Report
- March 2025
- 93 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 89 Pages
Global
From €5316EUR$5,600USD£4,484GBP
- Report
- March 2025
- 244 Pages
Global
From €5174EUR$5,450USD£4,364GBP
- Report
- March 2025
- 193 Pages
Global
From €5174EUR$5,450USD£4,364GBP
- Report
- March 2025
- 246 Pages
Global
From €4699EUR$4,950USD£3,964GBP
- Report
- March 2025
- 197 Pages
Global
From €4699EUR$4,950USD£3,964GBP

Continuous bioprocessing is a biotechnology-based approach to the production of biopharmaceuticals, such as vaccines, monoclonal antibodies, and recombinant proteins. It involves the use of continuous manufacturing techniques, such as continuous cell culture, continuous chromatography, and continuous purification, to produce biopharmaceuticals in a more efficient and cost-effective manner than traditional batch-based processes. This approach also allows for greater control over the production process, resulting in higher quality products.
Continuous bioprocessing has become increasingly popular in recent years, as it offers a number of advantages over traditional batch-based processes. These include improved process control, increased product yield, reduced production costs, and shorter production times.
Some companies in the continuous bioprocessing market include Merck KGaA, Novartis, Pfizer, Sanofi, and Lonza. Show Less Read more